End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.66 USD | -1.66% |
|
-7.55% | -58.51% |
Valuation
Fiscal Period: December | 2023 |
---|---|
Capitalization 1 | - |
Enterprise Value (EV) 1 | - |
P/E ratio | -18.2 x |
Yield | - |
Capitalization / Revenue | - |
EV / Revenue | - |
EV / EBITDA | - |
EV / FCF | - |
FCF Yield | - |
Price to Book | -124 x |
Nbr of stocks (in thousands) | - |
Reference price 2 | 25.69 |
Announcement Date | 27/03/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Net sales 1 | 102.3 | 113.4 |
EBITDA 1 | 10.33 | 20.33 |
EBIT 1 | 9.203 | 19.21 |
Operating Margin | 9% | 16.94% |
Earnings before Tax (EBT) 1 | 9.412 | -76.96 |
Net income 1 | 2.302 | -92.93 |
Net margin | 2.25% | -81.92% |
EPS 2 | 0.0300 | -1.412 |
Free Cash Flow | - | 20.67 |
FCF margin | - | 18.22% |
FCF Conversion (EBITDA) | - | 101.69% |
FCF Conversion (Net income) | - | - |
Dividend per Share | - | - |
Announcement Date | 27/03/24 | 27/03/24 |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Net Debt 1 | - | - |
Net Cash position 1 | 24.6 | 33.1 |
Leverage (Debt/EBITDA) | - | - |
Free Cash Flow | - | 20.7 |
ROE (net income / shareholders' equity) | - | -113% |
ROA (Net income/ Total Assets) | - | 11.9% |
Assets 1 | - | -778.9 |
Book Value Per Share 2 | 0.6700 | -0.2100 |
Cash Flow per Share 2 | 0.4000 | 0.4400 |
Capex 1 | 4.99 | 8.52 |
Capex / Sales | 4.87% | 7.51% |
Announcement Date | 27/03/24 | 27/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-58.51% | 882M | |
+37.76% | 52.5B | |
-7.47% | 39.01B | |
+37.72% | 39.31B | |
+11.93% | 26.2B | |
-11.17% | 26.57B | |
+16.45% | 28.2B | |
+45.05% | 14.15B | |
+33.13% | 12.62B | |
-3.46% | 11.74B |
- Stock Market
- Equities
- GYRE Stock
- Financials Gyre Therapeutics, Inc.